Roots Analysis

NOVEMBER 30, 2021

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Companies Offering Bioassay Services for Cell and Gene Therapies.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

pharmaphorum

SEPTEMBER 26, 2022

The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Download the full event guide to find out more.

Gene Therapy 52

Gene Therapy Gene Development Bioassay 52

pharmaphorum

JANUARY 21, 2021

The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development, supporting a seamless transition to the larger scales required for commercialization. The post Gene Therapy Comparability appeared first on.

Gene Therapy 52

Gene Therapy Gene Bioassay Manufacturing 52

Roots Analysis

JANUARY 16, 2023

Gene Editing beyond CRISPR Market, 2022-2035. Cell and Gene Therapy Bioassay Services Market, 2021-2030. Further, owing to the various advantages offered by the AHST, such as cost effectiveness, the demand for such kits is likely to increase in the coming years. Our Social Media Platform. Facebook – [link].

Bioassay 52

Bioassay Gene Editing Marketing Gene Therapy 52

Drug Discovery World

NOVEMBER 9, 2023

Advances in analytical techniques and approaches This session is made up of four presentations which include: Christian Graf, PhD, Fellow, Scientific Office, Novartis TRD Biologics, on: ‘MS-based cell bioassays: A novel tool for biotherapeutics characterisation’. The session ends with two presentations and two luncheon presentations.

Engineer 52

Engineer Antibody Protein In-Vivo 52